Malignant pleural mesothelioma: Medical treatment update

Clinical Lung Cancer

Volumn 10, Issue 2, 2009, Pages 112-117

  Vorobiof, Daniel A ^a   Mafafo, Keorapetse ^a  

^a Sandton Oncology Center   (South Africa)

Author keywords

Antimetabolites; Asbestos; Camptothecins; Cisplatin; Pemetrexed; Pleura; Targeted therapy; Taxanes

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTHRACYCLINE; ANTIMETABOLITE; AZACITIDINE; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DASATINIB; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IFOSFAMIDE; INTERFERON; MITOMYCIN; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SORAFENIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCA ALKALOID;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MONOTHERAPY; PLEURA MESOTHELIOMA; TREATMENT RESPONSE;

EID: 65349196092     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.014     Document Type: Review

References (105)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the Northwestern Cape Province. Br J Ind Med 1960; 17:260-71.
2. Webster I. Asbestosis and malignancy. SAMJ 1973; 47:165-71.
3. Vorobiof DA. Progress in the medical treatment of malignant pleural mesothelioma. Cancer Chemother Rep 2006; 1:107-13.
4. Cochrane JC, Webster I. Mesothelioma in relation to asbestos fiber exposure. A review of 70 serial cases. S Afr Med J 1978; 54:279-81.
5. Zvi AB, Reid G, London S P, et al. Mesothelioma in South Africa 1976-84: incidence and case characteristics. Int J Epi 1989; 18:320-29.
6. Abratt R P, White NW, Vorobiof DA. Epidemiology of mesothelioma - a South African perspective. Lung Cancer 2005; 49(suppl 1):S513-15.
7. Carbone M, Emri S, Dogan AU. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7:147-54.
8. Pass HI, Donington JS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumour antigen DNA sequences. J Thorac Cardiovasc Surg 1998; 116:854.
9. Byrne M, Hillerdal G. Imaging, staging and response evaluation. Lung Cancer 2005; 49(suppl):S25-26.
10. Van Meerbeeck J P, Boyer M. Consensus report: pretreatment minimal staging and treatment of potentially resectable MPM. Lung Cancer 2005; 49(suppl 1):S123-27.
11. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173:1155-60.
12. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85(1):265-72.
13. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564-73.
14. Rusch V W. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997; 9:367.
15. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. J Thorac Cardiovasc Surg 2004; 128(1):138-46.
16. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14:1007-1017.
17. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113:665-735.
18. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-35.
19. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981-85.
20. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophos-phamide in diffuse malignant mesothelioma. Cancer Treat Rep 1985; 69:1431-32.
21. Kaukel E, Koschel G, Gatzemeier U, et al. A phase II study of pirarubicin in malignant mesothelioma. Cancer 1990; 66:651-54.
22. Colbert N, Vannetzel JM, Israel V, et al. A prospective trial of detorubicin in malignant mesothelioma. Cancer 1985; 56:2170-74.
23. Magri MD, Veronesi A, Foladore S, et al. Epirubicin treatment of malignant mesothelioma: a phase II cooperative study. Northeastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori 1991; 77:49-51.
24. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothe-lioma: a phase II study of the EORTC Lung Cancer Cooperative Group. J Clin Oncol 1992; 10:824-28.
25. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000; 18:243-45.
26. Baas P, van Meerbeeck J, Groen H, et al. Caelyx in malignant mesothelioma. A phase II EORTC study. Ann Oncol 2000; 11:697-700.
27. Hillerdal G, Brodin O, Hjerpe A, et al. Malignant pleural mesothelioma: treatment with liposomized doxorubicin. A phase II Scandinavian study. Eur J Cancer 2001; 37:S44.
28. Steele J P, O'Doherty CA, Shamash J, et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001; 12:497-99.
29. Eisenhauer EA, Evans WK, Raghavan D, et al. Phase II study of mitoxantrone in patients with malignant pleural mesothelioma. A National Cancer Institute of Canada Clinical Trial Group study. Cancer Treat Rep 1986; 70:1029-30.
30. Van Breukelen FJM, Mattson K, Giaccone G, et al. Mitoxantrone in MPM. A study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991; 27:1627-33.
31. Falkson G, Vorobiof DA, Lerner HJ. A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 1983; 11:94-97.
32. Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: a phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988; 80:698-700.
33. Zidar BL, Metch B, Balcerzak S P, et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Cancer 1992; 70:2547-51.
34. Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337-43.
35. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant meso-thelioma. Cancer Treat Rep 1987; 71:857-58.
36. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988; 6:223-26.
37. Mintzer DM, Kelsen D, Frimmer D, et al. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69:711-12.
38. Planting AST, Schellens JHM, Goey SH, et al. Weekly high dose cisplatin in MPM. Ann Oncol 1994; 5:373-74.
39. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in mesothelioma: a phase II study of the CALGB. Cancer Chemother Pharmacol 1990; 27:239-42.
40. Mbidde EK, Harland SJ, Calvert AH, et al. Phase II trial of Carboplatin (JM8) in the treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18:284-85.
41. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8:151-54.
42. Solheim O P, Saeter G, Finnanger AM, et al. High dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992; 65:956-60.
43. Kindler HL, Belani C P, Herndon JE, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC # 626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the CALGB. Cancer 1999; 86:1985-91.
44. Scagliotti G, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front line therapy in MPM. J Clin Oncol 2003; 21:1556-61.
45. Vogelzang NJ, Weissmann LB, Herndon JE, et al. Trimetrexate in malignant meso-thelioma: a CALGB phase II study. J Clin Oncol 1995; 12:1436-42.
46. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant meso-thelioma: phase II trials of single agent 5-fluorouracil and adriamycin. Cancer 1984; 54:961-64.
47. Kindler HL, Millard F, Herndon JE II, et al. Gemcitabine for malignant mesothe-lioma: a phase II trial by the CALGB. Lung Cancer 2001; 31:311-17.
48. Van Meerbeeck J P, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma.n Cancer 1999; 85:2577-82.
49. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine (Gemzar) may reduce tumor load and associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1998; 17:464 (Abstract 1784).
50. Falkson G, Vorobiof DA, Simpson IW, et al. Phase II trial of Acivicin (AT-25) in malignant mesothelioma. Cancer Treat Rep 1987; 71:545-46.
51. Kindler HL, Herndon JE, Vogelzang NJ, et al. CPT-11 in malignant mesothelioma: a phase II trial by the CALGB (CALGB 9733). Proc Am Soc Clin Oncol 2000; 19:505 (Abstract 1978).
52. Maksymiuk AW, Marschke R F, Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998; 21:610-13.
53. Vogelzang NJ, Herndon JE, Miller A, et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999; 10:597-600.
54. Van Meerbeeck J, Debruyne C, Van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-63.
55. Belani C P, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999; 18:474 (Abstract 1829).
56. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 2002; 13:412-15.
57. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothe-lioma: a negative report. Cancer Chemother Pharmacol 1989; 24:133-34.
58. Cowan JD, Green S, Lucas J, et al. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988; 6:247-48.
59. Kelsen D, Gralla R, Cheng E, et al. Vindesine in the treatment of malignant meso-thelioma; a phase II study. Cancer Treat Rep 1983; 67:821-22.
60. Boutin C, Irisson M, Guerin JC, et al. Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 1987; 71:205-6.
61. Steele J P, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912-17.
62. Talbot D, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007; 25:4751-56.
63. Sahmoud T, Postmus PE, Pottelsberghe CH, et al. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33:2211-16.
64. Tammilehto L, Maasilta P, Mantyla M, et al. Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 1994; 5:949-50.
65. Giaccone G, O'Brien M, Byrne M, et al. Current phase II data for ZD0473 in patients with mesothelioma who had relapsed following one previous chemotherapy regimen. Eur J Cancer 2001; 37:S45 (Abstract).
66. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of single weekly intravenous does of ranprinase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-81.
67. Vogelzang NJ, Herndon JE, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer 1997; 79:2237-42.
68. Dhingra HM, Murphy WK, Winn RJ, et al. Phase II trial of 5,6 dihydro-5-azacyti-dine in pleural malignant mesothelioma. Invest New Drugs 1991; 9:69-72.
69. Janne PA, Wang X F, Krug LM, et al. Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma:CALGB 30307. Lung Cancer 2006; 54(suppl 1):S51 (Abstract 211).
70. Garland L, Rankin C, Gandara D, et al. Phase II study of Erlotibin in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol 2007; 25:2406-13.
71. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Ca Res 2005; 11:2300-304.
72. Jahan TM, Wang GX, Kratzke RA, et al. Vatalanib for patients with previously untreated advanced malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol 2006; 24:384s (Abstract 7081).
73. Samson MK, Wasser L P, Borden EC, et al. Randomized comparison of cyclophos-phamide, imidazole carboxamide and Adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup study. J Clin Oncol 1987; 5:86-91.
74. Dhingra H, Valdivieso M, Tannir N, et al. Combined modality treatment for me-sothelioma with cytoxan and adriamycin, and DTIC and adjuvant surgery. Proc Am Soc Clin Oncol 1983; 2:20-205a (Abstract C-800).
75. Carmichael J, Cantwell BM, Harris AL. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 1989; 25:911-2.
76. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A phase II trial dose-escalated doxo-rubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994; 5:653-55.
77. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 1991; 67:2984-87.
78. Chahinian A P, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-65.
79. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination che- motherapy with cyclophosphamide, doxorubicin and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995; 76:2230-36.
80. Chahinian A P, Pajak T F, Holland J F, et al. Diffuse malignant mesothelioma. Ann Intern Med 1982; 86:746-55.
81. Upham JW, Musk AW, van Hazel G, et al. Interferon α and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993; 2316:683-87.
82. Pennuci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. A phase II FONI-CAP trial. Cancer 1997; 54:1897-902.
83. Breau JL, Boaziz C, Morere JJF, et al. 1991. Combination therapy with cisplatin, adriamycin, bleomycin and mitomycin C, plus systemic and intrapleural hyaluroni-dase in 25 consecutive cases of stage II, III pleural mesothelioma. Paper presented at the First International Mesothelioma Conference, Paris.
84. Magri MD, Foladore S, Veronesi A, et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II comparative study. Ann Oncol 1992; 3:237-38.
85. Zidar BL, Benjamin RS, Frank J, et al. Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. Am J Clin Oncol 1983; 6:71-74.
86. Koschel G, Calavrezos A, Kaukel E, et al. Phase III randomized comparison of pirarubicin versus pirarubicin and cisplatin for treatment of pleural mesotheliomas. Proc Sixth European Congress Against Cancer 1991.
87. Samuels BL, Herndon JE, II, Harmon DC, et al. Dihydro-5-azacytidine and cispla-tin in the treatment of malignant mesothelioma. A phase II study of the Cancer and Leukemia Group B. Cancer 1998; 82:1578-84.
88. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994; 11:305-308.
89. Tansan S, Emri S, Selcuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and α interferon. Oncology 1994; 51:348-51.
90. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemo-immunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study weekly cisplatin/interferon α-2a. J Clin Oncol 1996; 14:878-85.
91. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25-30.
92. Van Haast JMW, Baas P, Manegold C, et al. Multicenter phase II study of Gemcitabi-ne and Cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86:342-45.
93. Kindler HL, van Meerbeeck J P. The role of Gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002; 29:70-76.
94. Nowak A, Byrne M, Williamson R, et al. Multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma. Ann Oncol 2000; 11:109.
95. Aversa SML, Favaretto AG. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999; 1:73-75.
96. Vogelzang N, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in malignant pleural mesothe-lioma. J Clin Oncol 2003; 21:2636-44.
97. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxalipla-tin an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003; 21:349-54.
98. Castagneto B, Mencoboni M, Degiovanni D, et al. Pemetrexed and carboplatin in the treatment of advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2006; 24:387s [abstract 7093].
99. Boyar MS, Hesdorffer M, Taub RN. Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural and peritoneal mesothelioma. Proc Am Soc Clin Oncol 2006; 24:677s (Abstract 17133).
100. Hillerdal G, Sorensen JB, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with gemcitabine, carboplatin and liposomized doxorubicin (Cae-lyx®); The CCG study from the Nordic mesothelioma groups. Lung Cancer 2006; 54(suppl 1):S48 (Abstract 205).
101. Van Meerbeeck J P, Manegold C, Gaafar R, et al. A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothe-lioma. An intergroup study of the EORTC lung cancer group and NCIC. J Clin Oncol 2005; 23:6881-89.
102. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multicentre double-blind, placebo controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. Proc Am Soc Clin Oncol 2007; 25:7526.
103. Janne P, Simon G, Langer C, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy native malignant pleural mesothelioma. J Clin Oncol 2008; 26:1465-71.
104. Sorenson JB, Sundstrom S, Perell K, et al. Pemetrexed second-line treatment in malignant pleural mesothelioma following platinum-based first-line treatment. Lung Cancer 2006; 54(suppl 1):S46 (Abstract 192).
105. Zucali PA, Garassino GL, Ceresoli F, et al. Treatment with gemcitabine and vinorel-bine (GEMVIN) as second-line chemotherapy in pemetrexed pretreated patients with malignant pleural mesothelioma. Lung Cancer 2006; 54(suppl 1):S48 (Abstract 201).